Antibiotic Therapies for Urinary Tract Infections and Their Impact on the Gut Microbiota

NCT07424989 | Completed

• 1 other identifier: 2019/329/OB
• Study Type: observational
• Target: 61
• Locations: 1 country
• Sites: 1

Brief Summary

A urinary tract infection requires antibiotic treatment. While this treatment is intended to eliminate bacteria from the urine, it may also facilitate the development of resistant strains in the digestive tract. Patients are asked to provide stool samples on several occasions so that any potential side effects of this treatment on the digestive flora can be analysed.

Conditions

Urinary Tract Infection(UTI)

Keywords

systemic antibiotic therapy; urinary tract infection; enteric carriage of EC3GR; stools

Outcome Measures

Primary Outcomes (1)

• Assessing the alteration of the gut microbiota induced by initial antibiotic therapy for urosepsis.

  Impact of initial antibiotic therapy on the increase in EC3GR enteric carriage defined as: * Positive EC3GR culture in stool sample 30-35 days after the end of antibiotic treatment (FT+30-35) in a patient with a negative (i.e. undetectable) EC3GR culture in stool sample on day 0 (D0) * Or a tenfold increase in the relative abundance of EC3GR between stool samples taken on D0 and FT-30-35 in patients with a positive EC3GR culture in stool samples taken on D0

  From enrollment to 30-35 days after the end of antibiotic treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients will be recruited via the Emergency Department (ED).

You may qualify if:

• Adult patient requiring hospitalisation
• Diagnosis of urinary tract infection requiring systemic antibiotic therapy with ceftriaxone, piperacillin/tazobactam or temocillin
• Collection of a stool sample possible before or within 24 hours of starting systemic antibiotic therapy
• Patient who has read and understood the information letter and given their consent to participate in the research

You may not qualify if:

• Minor patient
• Patient hospitalised in an intensive care unit
• Digestive stoma
• Patient not affiliated with social security
• Pregnant woman, woman in labour or breastfeeding woman
• Person deprived of liberty by administrative or judicial decision
• Person placed under judicial protection, guardianship or curatorship

Sponsors & Collaborators

• University Hospital, Rouen: lead

Study Sites (1)

CHU de Rouen

Rouen, 76031, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

* Collection of stool samples using a sterile device that limits contamination * Collection of two stool samples using (i) a device that allows live bacteria to be stored at room temperature for up to 72 hours, (ii) a device that allows genetic material (DNA, RNA) to be stored for up to seven days.

MeSH Terms

Conditions

Urinary Tract Infections

Condition Hierarchy (Ancestors)

Infections; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 13, 2026
• First Posted: February 20, 2026
• Study Start: July 4, 2021
• Primary Completion: May 28, 2025
• Study Completion: May 28, 2025
• Last Updated: February 24, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)